Jul 19 |
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
|
Jul 12 |
Aurinia (AUPH) Soars 6.6%: Is Further Upside Left in the Stock?
|
Jul 5 |
Aurinia Pharmaceuticals Appears Undervalued
|
Jun 28 |
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) most popular amongst retail investors who own 54% of the shares, institutions hold 35%
|
Jun 17 |
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
|
Jun 14 |
Aurinia Announces 2024 Annual General Meeting Results
|
Jun 8 |
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now
|
Jun 5 |
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
|
Jun 4 |
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
|
Jun 3 |
Aurinia Provides Update on Proxy Statement
|